Search results

26 items matching your search terms.
Filter the results.
Item type













New items since



Sort by relevance · date (newest first) · alphabetically
Diabetes drug lowers risk of cardiovascular complications, kidney disease
For the first time, a large clinical trial showed across-the-board cardiovascular benefit of a diabetes drug – liraglutide – a much-needed outcome for people with type 2 diabetes.
Located in News / 2016 / June
UNC clinical trials play crucial role in FDA approval for diabetes drug
Led by John Buse, MD, PhD, director of the UNC Diabetes Care Center, the clinical research of UNC doctors and the participation of thousands of patients culminates in a new, effective, and safe daily injectable drug to combat type-2 diabetes.
Located in News / 2016 / November
UNC Diabetes Care Center begins recruitment for long-term study of diabetes drug efficacy
Beginning recruitment in June, the project is called the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study. UNC will enroll patients at locations in Durham and Greensboro, N.C.
Located in News / 2013 / June
NIAID grant launches Kashuba's plan for HIV-prevention trials
Development of an AIDS vaccine is struggling. Topical treatments aimed at stopping HIV have made little progress. Angela Kashuba, PharmD, believes that antiretroviral drugs are the best hope for halting the spread of AIDS, especially in the developing world.
Located in Vital Signs / Archives / Vital Signs - Jan. 4, 2010
Results from many large clinical trials are never published
Non-publication is more common among industry-funded trials, study finds.
Located in News / 2013 / October
Researchers from UNC Lineberger, Norway launch cancer genetics collaboration
Researchers from Norway visited the cancer center last week to learn firsthand about UNCseq, a clinical trial launched in 2011 at the N.C. Cancer Hospital. In the trial, researchers use a profile of the genetic and molecular alterations in patients' tumors to try to identify targeted treatments for them.
Located in News / 2015 / September
Moving clinical trials overseas tests the system’s safety, efficacy
Major U.S. drug companies are increasingly performing clinical trials in developing countries, raising serious concerns about the efficacy, ethics and economics of drug development, according to a study by two UNC researchers in the current issue of the New England Journal of Medicine.
Located in Vital Signs / 2009 / February
Endovascular Aortic Repair Devices approved by the FDA Following Testing at UNC
Two endovascular aortic repair devices tested in clinical trials at the University of North Carolina School of Medicine have been approved by the U.S. Food and Drug Administration (FDA) for use in the United States.
Located in News / 2012 / September
UNC enrolling patients in Momentum 3 Clinical Trial
UNC is one of 60 medical centers nationwide chosen to participate in the MOMENTUM 3 Clinical Trial to evaluate the effectiveness and safety of the Thoratec® HeartMate 3™ Left Ventricular Assist Device (LVAD). This multi-center study will compare the HeartMate 3 LVAD to the HeartMate II® LVAD in advanced stage heart failure patients.
Located in News / 2015 / November
Rifaximin provides significant relief of irritable bowel syndrome symptoms
Two studies, conducted in part at the UNC School of Medicine, found that the benefits of treatment with rifaximin persisted for 10 weeks after patients stopped taking the broad-spectrum antibiotic.
Located in News / 2011 / January